MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
*Funding: Surgery_Surgical Technology, Minimally Invasive & Operating Room of the Future (ORF)
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
Forbion Capital Partners
Finance & Acquisition: Forbion
Parents
Forbion Capital Partners
Children
2021: $68.5M Series A financing led by Forbion, and accompanied by Morningside Venture Investments, Sectoral Asset Management, Talisman Capital Partners and ALS Investment Fund.
2021: Investors in the firm have invested at least $235 million and include Syncona, RA Capital Management, Forbion Capital, and Baker Bros. Advisors.
2021: Series C led by Forbion, Sofinnova Investments, T. Rowe Price Associates, Tetragon Financial Group, Fosun Pharma, Syncona, and Cambridge Innovation Capital.
2022: Financing led by Brandon Capital, Forbion and Atlas Venture
2023: Forbion leads Series A, with participation from founding seed investor OrbiMed and additional new investors RA Capital Management and HealthCap
2023: Series A funded by Atlas Venture, Bain Capital Life Sciences, Forbion, Sofinnova Investments, and RA Capital Management
2024: Backed by Dutch investor Forbion, IP Group, NeoMed and V-Bio Ventures.
2024: Capstan also has major institutional investors who participated in its latest fundraising round, including Forbion, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, OrbiMed, Polaris Partners and Vida Ventures.
2024: Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona
2024: The funding round was co-led by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.), Forbion and Novartis Venture Fund, with the participation of Pureos Bioventures, alongside existing investors BioGeneration Ventures, Seventure Partners, BOM, Curie Capital, and Citryll’s founders.
2025: Financing co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital
2025: Financing led by NEA with new investors Lilly Ventures, Cormorant, the Export and Investment Fund of Denmark and founding investors Novo Holdings and Forbion
2025: Financing was co-led by Cormorant Asset Management, Forbion via its Forbion Growth Opportunities Fund, HBM Healthcare Investment, and Novo Holdings, with participation from other existing investors BVF Partners L.P., Octagon Capital Advisors LP, RTW Investments, and funds and accounts managed by BlackRock.
Existing participating investors included NGN Capital and Forbion Capital Partners
Forbion Capital Partners, a Dutch venture capital firm, led the expansion of the company’s Series A financing round
Has obtained $33 million in a third round of financing led by venture capital firms Forbion Capital Partners and Endeavour Vision.(2011)
Investors are Forbion Capital Partners, Giza Venture Capital, HLM Venture Partners, Latterell Venture Partners, Oxford Bioscience Partners, WRF Capital, and individual investors
Investors: Advent Life Sciences, BioMotiv, Eli Lilly and Company, Forbion, Gilde Healthcare and Novartis Venture Fund funded the series B.
Led by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, Life Sciences Partners, BioGeneration Ventures, Erasmus Biomedical Fund, Thuja Capital, and Flemish research institute VIB
OrbiMed Advisors and Seventure Partners co-led the round, and were joined by return backers Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, Erasmus Biomedical Fund, Thuja Capital and VIB.
Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Vesalius BioCapital and Life Sciences Research Partners.
Participants include Forbion Capital Partners, Morningside Group and New Science Ventures
Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.
Raised $30 million in Series D funding (2011): MacAndrews & Forbes Holdings and return backer Forbion Capital Partners co-led the round, and were joined by Crédit Agricole Private Equity, Saints Capital, Foundation Medical Partners and SB Life Science Vent
Round led by Forbion Capital Partners, Saints Venture Capital, Oxford Bioscience Partners, Triathlon Medical Ventures, Medtronic Corporation, Johnson & Johnson Development Corporation, Orchestra Medical Ventures, Oakwood Medical Investors, Palisade Capital
Series B financing round led by Edmond de Rothschild Investment Partners (EdRIP), with Forbion Capital Partners, Auriga Partners, NBGI Ventures, Credit Agricole Private Equity, Advent Venture Partners, HealthCare Ventures and NESTA
Series C Investor(s) Endeavour Vision, Silicon Valley Bank, Adams Street Partners, Telegraph Hill Partners, Spray Venture Partners, Forbion Capital Partners, Alta Partners, Leader Ventures
The company has raised more than $80 million in venture capital from The Aurora Funds, Forbion Capital Partners, Genechem, Intersouth Partners, Lumira Capital and TVM Capital.
The financing includes a new investor, ARCH Venture Partners, in addition to support from existing investors Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group
The financing was led by Fibrotic Ventures. It also received additional funding from existing venture investors such as Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.
Jumps
Key People: Forbion
Organization & Developments: Forbion